Silver

Silver

SCHEMBL218931

O=S(=O)([O-])CCS(=O)(=O)[O-].[Ag+].[Ag+]

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2

The experimentally established mechanism targets of Silver. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
MAPT P10636 1/20 0.53
ALOX15 P16050 1/20 0.53
ALDH1A1 P00352 2/20 0.47
TSHR P16473 2/20 0.47
TP53 P04637 2/20 0.47
GMNN O75496 1/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
THPO P40225 1/20 0.47
HBB P68871 1/20 0.47
PMP22 Q01453 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
BBOX1 O75936 3/20 0.43
ENPEP Q07075 2/20 0.38
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29265997 0.91 KDM4E (0.53) KDM4EMAPTALOX15ALDH1A1TSHR
SCHEMBL2521157 0.91 KDM4E (0.53) KDM4EMAPTALOX15ALDH1A1TSHR
SCHEMBL2288874 0.91 KDM4E (0.53) KDM4EMAPTALOX15ALDH1A1TSHR
SCHEMBL11359480 0.91 KDM4E (0.53) KDM4EMAPTALOX15ALDH1A1TSHR
SCHEMBL2524420 0.91 KDM4E (0.53) KDM4EMAPTALOX15ALDH1A1TSHR
Potassium Ion SCHEMBL8715930 0.91 KDM4E (0.53) KDM4EMAPTALOX15ALDH1A1TSHR
SCHEMBL218933 0.91 KDM4E (0.53) KDM4EMAPTALOX15ALDH1A1TSHR
SCHEMBL214687 0.91 KDM4E (0.62) KDM4EMAPTALOX15ALDH1A1TSHR
Lithium Ion SCHEMBL1458081 0.91 KDM4E (0.53) KDM4EMAPTALOX15ALDH1A1TSHR
SCHEMBL29265992 0.91 KDM4E (0.53) KDM4EMAPTALOX15ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9647294-B2 Non-aqueous electrolytic solution, electrochemical element using same, and alkynyl compound used therefor UBE INDUSTRIES, LTD. (JP) 2017-05-09 US disclosed
US-9624238-B2 4H-thieno[3,2-C]chromene-based inhibitors of Notum Pectinacetylesterase and methods of their use LEXICON PHARMACEUTICALS, INC. (US) 2017-04-18 US disclosed
EP-2533344-B1 NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING THE SAME, AND ALKYNYL COMPOUND USED THEREFOR UBE INDUSTRIES (JP) 2016-07-20 EP disclosed
EP-2883867-A2 Non-aqueous electrolytic solution, electrochemical element using the same and alkynyl compound used therefor Ube Industries, Ltd. (JP) 2015-06-17 EP disclosed
US-20140256784-A1 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE OXFORD FINANCE LLC, AS COLLATERAL AGENT 2014-09-11 US disclosed
EP-2533344-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING SAME, AND ALKYNYL COMPOUND USED THEREFOR Ube Industries, Ltd. (JP) 2012-12-12 EP disclosed
US-20120301797-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING SAME, AND ALKYNYL COMPOUND USED THEREFOR UBE INDUSTRIES, LTD. (JP) 2012-11-29 US disclosed
US-20120302562-A1 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS, INC. 2012-11-29 US disclosed
US-8088548-B2 Bottom antireflective coating compositions AZ ELECTRONIC MATERIALS USA CORP. (US) 2012-01-03 US disclosed
US-20090104559-A1 Bottom Antireflective Coating Compositions MERCK PATENT GMBH (DE) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090104559-A1 Bottom Antireflective Coating Compositions SDC2, S100A9, MYH9 KDM4E 934/4885MAPT 971/4885ALOX15 2763/4885
US-20140256784-A1 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE NOTUM, CES1, ACHE KDM4E 333/4885MAPT 3769/4885ALOX15 1502/4885
US-20120302562-A1 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE NOTUM, CES1, ACHE KDM4E 333/4885MAPT 3769/4885ALOX15 1502/4885
US-20120301797-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING SAME, AND ALKYNYL COMPOUND USED THEREFOR WEE2, WEE1, NOTUM KDM4E 764/4885MAPT 4811/4885ALOX15 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.